Latest news with #TMO
Extra.ie
2 days ago
- Sport
- Extra.ie
Criticism and scrutiny of Sam Prendergast has gone too far
Leinster got their groove back on Saturday. A hapless Glasgow side – the defending champions, lest we forget – felt the full force of a vengeful team, which is on a mission to secure a first trophy for the province in four seasons. After all the recent criticism, virtually every player on the pitch delivered a top-class performance. Andrew Porter and Dan Sheehan looked like Test Lions-in-waiting, while Thomas Clarkson, who was filling in for the stricken Tadhg Furlong at tighthead, delivered arguably the most compelling performance of his fledgling career. Sam Prendergast. Pic: Seb Daly/Sportsfile Joe McCarthy and James Ryan were ferocious on both sides of the ball. Again, both second rows are primed to have big summers with Andy Farrell's tourists in Australia. Ryan Baird went home with the player-of-the-match award after 80 minutes of relentless industry. Scott Penny showed up well. Jack Conan led from the front. Not bad for a backrow unit missing Josh van der Flier and Caelan Doris. Jamison Gibson-Park was as sharp as ever. Jordie Barrett was rock solid. Jamie Osborne capped off a busy shift with a brace of tries. Tommy O'Brien and James Lowe brought heaps of energy. Jimmy O'Brien, filling in for the injured Hugo Keenan, caught the eye, too. Ronan Kelleher, RG Snyman, Max Deegan and Ciaran Frawley brought energy from the bench while Ross Byrne delivered his customary calm and poise when he entered the fray. Jordie Barrett Pic: Tyler Miller/Sportsfile There was one outlier in an otherwise dominant display from the hosts. Sam Prendergast didn't have his best outing. Once again, the young Leinster out-half delivered a mixed performance. Yes, Leinster's attack hummed and fizzed with intent all afternoon. The hosts crossed for six tries and had two more chalked off by TMO interventions. If anything, the 37-19 scoreline flattered the Scots in the end. It could have even been greater if Prendergast didn't have such an off-day with the kicking tee, missing four conversions, a penalty and a drop-goal during an unconvincing shift. Once again, Prendergast's defence was suspect at key moments. None of this is new. And, ahead of Saturday's URC Grand Final against a physically imposing Bulls side, there is a genuine case to be made for Byrne or Frawley to wear the No10 jersey. Leo Cullen. Pic: David Fitzgerald/Sportsfile It's doubtful that Leo Cullen will make such a radical change at this stage. The Leinster supremo has backed Prendergast as playmaker-in-chief all season. It would be a radical move to bench his first-choice out-half in the week of such a pivotal game. No doubt, there will be plenty of scrutiny about Prendergast's performance against Glasgow in the coming days. It's been the same story all season. You'd wonder if the Kildare native is a bit worn down from constantly being under this rugby-shaped microscope. At the end of the day, this is the reality of being a professional rugby player in this country. No player should be immune from critical analysis. When it comes to assessing the strengths and weaknesses of Prendergast's game, however, a lot of the criticism has crossed the line. It's worth pointing out that Prendergast is still only 22 and this is essentially his first full season at the top level. He only made his international debut in November, as a second-half replacement against Argentina, and has gone on to win a further seven caps for his country. For context, Johnny Sexton made his Test bow at age 24. Prendergast has been learning on the job. His development was accelerated by Andy Farrell who saw immense potential in a player who spearheaded a talented Ireland U20s team which made a Junior World Cup final in the summer of 2023. Sam Prendergast. Pic: Seb Daly/Sportsfile The Ireland head coach brought Prendergast into the national setup despite the fact that he was behind the Byrne brothers and Frawley in the Leinster pecking order. The penny seemed to drop with Cullen, with the Leinster boss turning to Prendergast to lead Leinster in this campaign. Prendergast started his first Champions Cup game (against Bristol) and his first interpro (against Munster) in December. He started four straight Six Nations games before making way for Jack Crowley ahead of the final-round clash with Italy in Rome. It's been a meteoric rise for such a young player in such a pivotal position. And the outside noise has been deafening at times. Prendergast has been love-bombed by certain commentators and loathed by others. Not so long ago, some observers – including some former Lions and prominent pundits – were installing Prendergast as the leading contender to wear the No10 shirt against Joe Schmidt's Wallabies this summer. Meanwhile, there has been some vitriolic criticism of Prendergast across social media, particularly from a cohort of Munster supporters who feel that Crowley had been unfairly usurped as Ireland's first-choice No10. Said fans have been angered by the so-called 'Leinsterification' of the national team. Both viewpoints have been extreme and unwarranted. Prendergast is far from the finished article. He isn't physically or mentally ready to boss a Lions Test series. But he doesn't deserve to be ridiculed by faceless fan accounts on social media either. Jack Crowley. Pic: INPHO/Dan Sheridan A video mocking Prendergast's attempted tackle on Henry Pollock began to do the rounds across WhatsApp in the days after Leinster's Champions Cup semi-final defeat against Northampton. It was cheap and mean spirited. We're veering into cyberbullying territory. We're not talking about a seasoned Test veteran here. This is a young man who has been thrown in at the deep end because his province felt he had the highest ceiling among a stable of talented out-halves while the international management felt he was a player who could have a major impact at the 2027 World Cup, and beyond. You'd hope that all is this outside noise hasn't had any lasting effects on Prendergast. In November 2023, England legend Owen Farrell announced he would be giving the 2024 Six Nations a swerve to 'prioritise his and his family's wellbeing.' Farrell subsequently signed for Racing 92 and hasn't been seen in an England shirt since. Just like Prendergast, the 33-year-old has been a lightning rod for online barbs and relentless scrutiny. Farrell voted with his feet. He had enough of all the negativity. He wasn't enjoying it anymore. You'd hate to think that Prendergast would feel compelled to do something similar. He doesn't look like someone whose enjoying all this attention at the moment. Maybe it's time for people to give the kid a break.
Yahoo
30-05-2025
- Business
- Yahoo
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
Thermo Fisher Scientific TMO has unveiled its latest innovation, the spectral-enabled Invitrogen Attune Xenith Flow Cytometer. The solution allows immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples. The Attune Xenith Flow Cytometer is the latest advancement in the company's extensive portfolio of flow cytometry solutions, including the Attune CytPix and NxT instruments. After the announcement yesterday, TMO shares edged up 0.8%, closing at $403.75. Given that the company has a strong track record of advancing scientific knowledge by offering innovative tools that enhance lab efficiency, data accuracy and overall research capabilities, we expect that the latest development will positively boost the market sentiment toward TMO stock. Presently, Thermo Fisher boasts a market capitalization of $151.80 billion. The Zacks Consensus Estimate forecasts a 2.1% increase in the company's earnings and 1.9% growth in revenues, both on a year-over-year basis. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.3%. As the field of flow cytometry grows and research needs become more complex, scientists require access to even more data from cells, which can help provide insights into how diseases, including cancer, manifest and progress in the body. Traditional cytometers frequently face issues with complex data analysis, non-intuitive interfaces and frequent clogs, which can slow down the research process and cause waste of often irreplaceable tissue samples. Image Source: Zacks Investment Research The Attune Xenith Flow Cytometer features the legacy core acoustic focusing technology, which accelerates sample analysis, significantly reducing processing times while maintaining exceptional sensitivity. Its clog-resistant design reduces stoppages and sample waste to allow labs to operate more reliably with minimal sample volume. Additionally, the instrument is equipped with six lasers and 51 fluorescent detectors, enabling detailed and accurate insights from each sample. Lastly, the Attune Xenith Flow Cytometer is designed for extended operation without needing fluid changes, maximizing lab productivity. Built-in cameras, automated maintenance and remote diagnostics help ensure ease of use for researchers of all experience levels. Per a Research report, the flow cytometry market was valued at $4.68 billion in 2024 and is expected to witness a compound annual growth rate of 8.4% through 2030. Key factors fueling the market's growth are the increasing incidences of cancer, immunodeficiency disorders and infectious diseases. Moreover, heightened research and development investments in biotechnology, life science and biopharmaceutical research have contributed to a leveraged demand for flow cytometry instruments. Last week, the company introduced the Thermo Scientific TruNarc Delta and Tau Handheld Narcotics Analyzers to help communities combat known and emerging narcotics and illicit substances. The user-friendly devices come with touchless technology and an expanded chemical library, empowering frontline law enforcement officials to identify more than 1,200 substances in the field. In the past three months,TMO shares have fallen 22.9% compared with the industry's 11.2% decline. Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry's 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 172.5% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare's fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry's 10.1% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Irish Examiner
27-05-2025
- Sport
- Irish Examiner
Duncan Casey: If the TMO must intervene, Champions Cup final was a model of efficiency
As finals go, that was pretty damn good. Deciding matches of major rugby tournaments often leave a lot to be desired, a combination of nerves and percentage based, cup final strategies resulting in duller affairs than we would like. While a tight result indicates a good battle one way or another, we are rarely treated to the spectacle of free-flowing attacking rugby we would all love to see. It's fair to say that neither Northampton nor Bordeaux played quite to the level they are capable of on Saturday, both sides guilty of a sloppiness and proneness to error we did not see from them in the semi-finals. Despite this, they still treated us to a gripping display featuring plenty of excellent rugby, quality scores and no shortage of drama. There were numerous standout individuals over the 80 minutes, none more so than the TMO, Marius Jonker. This is exclusive subscriber content. Already a subscriber? Sign in Subscribe to access all of the Irish Examiner. Annual €120€60 Best value Monthly €10€4 / month Unlimited access. Subscriber content. Daily ePaper. Additional benefits.
Yahoo
23-05-2025
- Business
- Yahoo
2 S&P 500 Stocks to Buy Now On the Dip for Huge Upside
The stock market barely budged on Thursday after its mid-week, Treasury yield-induced pullback. The bulls are trying to hold ground at the post-Trump election gap-up in their pursuit of all-time highs. That said, the market is likely due for a cooldown at some point soon following the massive rally off the April lows. Stocks could give up some of their recent gains if yields continue to climb on rising fears that investors are losing their appetite for U.S. debt. Image Source: Zacks Investment Research Thankfully, the next drop likely won't last long if the U.S. makes tangible trade deal progress and inflation continues to cool. On top of that, the strong earnings results and outlook must remain in place over the summer. Investors might not want to 'chase' soaring tech stocks to close out May. Thankfully, we all still have a chance to buy into weakness on plenty of strong large cap stocks trading miles below their records. Some people who might rush to buy a car, TV, or fill-in-the-blank when they go on sale by 10%, 25%, or even 50% might hesitate to strike when stock prices fall. But buying stocks when they have dropped significantly makes more sense because they are appreciating assets, unlike most other things people buy on sale. Today's Full Court Finance at Zacks dives into two beaten-down S&P 500 stocks—Thermo Fisher Scientific and Lululemon—to consider buying now for huge upside. Thermo Fisher Scientific (TMO) is a global leader in medical and lab equipment, specialty diagnostics tools, reagents, and more. TMO's growing portfolio serves companies across biotech, healthcare, and pharmaceuticals, providing them with a wide range of products essential to innovation and daily operation. TMO grew its revenue from under $5 billion in 2005 to $45 billion in 2022, capped off by a COVID-based boom. Image Source: Zacks Investment Research Thermo Fisher stock has tumbled 40% from its late 2021 peaks due to post-COVID demand normalization and other setbacks such as a biotech funding crunch. It offered disappointing guidance again in late April, driven by macroeconomic uncertainty and trade policy setbacks given its exposure to Chinese supply chains and the possible negative impact from proposed research funding cuts. Image Source: Zacks Investment Research TMO, which lands a Zacks Rank #3 (Hold), is projected to grow its revenue by 2% in 2025 and 7% in 2026 to climb solidly above its 2022 records. The company is expected to grow its adjusted earnings by 2% and 11%, respectively. This outlook means 2024 and 2025 will mark the bottom of Thermo Fisher's business cycle. Image Source: Zacks Investment Research The life sciences supplier stock has skyrocketed by over 1,400% in the past 20 years to triple the S&P 500. The outperformance includes its 40% dive from its late 2021 peaks. TMO stock is attempting to hold its ground at its summer 2020 breakout levels while trading at its most oversold RSI levels since 2008/09. The selloff has Thermo Fisher trading at some of its lowest valuation levels in the past decade and at a discount to its sector at 17.1X forward earnings (despite climbing 200% in the past 10 years vs. its sector's -8% decline). Lululemon (LULU) shares have soared nearly 1,500% in the last 15 years, leaving the market, Nike, and its sector in the dust. The athleisure power changed fashion during this period, sparking a wave of upstarts and apparel giants to fight for market share in a category Lululemon pioneered. LULU is finally facing slowing growth in the U.S. and North America after a banner stretch of expansion that saw it average 23% revenue growth between 2018 and 2023. The rapid boom of rivals Alo, Vuori, and countless other online-only startups are also contributing to LULU's slowing comparable store sales in its critical Americas region. Image Source: Zacks Investment Research The apparel titan grew its 2024 sales by 10%, with comps up 4%. But it provided downbeat guidance in late March, hurt by cautious consumers and other headwinds. Lululemon remains focused on executing its Power of Three ×2 growth plan (doubling sales between 2021 and 2026), on the back of huge growth across men's, e-commerce, and international. The company also expanded its operating margin by 40 basis points to 28.9% last year, which is a level almost unmatched in the nonluxury apparel space. Image Source: Zacks Investment Research Lululemon is projected to grow its revenue by 6% in 2025 on 4% comps expansion and then jump 8% next year to help boost its adjusted earnings by 1.4% and 10%, respectively. The company has topped our EPS estimates for nearly five years running and its long-term earnings growth outlook is strong. Image Source: Zacks Investment Research LULU trades 38% below its peaks, and it is down 17% in 2025 vs. its sector's 3% YTD pop. The recent struggles are part of a five-year chop following a stellar rally between 2014 and 2021. Lululemon held its ground once again at its pre-Covid selloff heights. Its recent rebound took it back above its 50-week moving average while trading at neutral RSI levels. Valuation-wise, the athleisure standout trades at some of its lowest ever levels at 20.8X forward earnings. This marks a 33% discount to its 15-year median and almost in line with its industry. The company also has a sturdy balance sheet with more cash and equivalents than current liabilities and zero debt. Lululemon will release its first quarter fiscal 2025 financial results on Thursday, June 5. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report lululemon athletica inc. (LULU) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Irish Examiner
18-05-2025
- Sport
- Irish Examiner
Ronan O'Gara's La Rochelle tighten play-off grip with sharp victory over Montpellier
Ronan O'Gara's La Rochelle climbed to fifth in the Top 14 with a sharp 47-18 bonus-point win over fellow play-off chasers Montpellier at Stade Marcel Deflandre in the closing match of the Top 14's 24th weekend. Just two places in the top six remain open – and every side down to Lyon, in 11th, is still in the hunt as the regular season winds down – points in the bag are more important than points in potential. This was La Rochelle's first domestic try-scoring bonus since their win over Stade Francais on November 2. After Mael Moustin had given the visitors an early lead with a well-taken try, the Rochelais – with O'Gara serving the second week of his touchline and dressing room suspension up in the stadium gods – dominated the rest of the game. Antoine Hastoy got the home side of the scoreboard moving with a penalty, before wingers Jack Nowell and Dillyn Leyds combined to send the former over the line. Prop Thierry Paiva then crashed over to finish off a fast and furious spell in which both sides turned over the ball in the visitors' 22. And Hastoy completed the first-half scoring with his second on-the-hooter drop goal in as many matches. His first gave La Rochelle their third win in a row at Vannes last Saturday. This one put them 15 points ahead – almost, but not quite out of sight. It wasn't all good news, however, as Uini Atonio did not come out for the second half, but the hosts continued to squeeze Montpellier out of the game. Levani Botia burst through a lineout maul to extend their lead just before the hour; Leyds acrobatically benefited from a Hastoy hack ahead five minutes later. He thought he had a dramatic second 10 minutes from time, racing clear after a determined defensive set from his forwards — but referee Pierre Brousset ruled it out following a lengthy TMO consultation and instead awarded a penalty try to Montpellier. With the last play of the game, however, Brice Dulin finished off a sweeping move to regain the try-scoring bonus. On Saturday, Matthieu Jalibert had the pundits purring with a consummate performance for Champions Cup finalists Bordeaux a week ahead of the showpiece against Northampton in Cardiff. He scored one special try and made two more equally impressive ones as his side came back from 14-0 down against Castres at Stade Chaban Delmas to lead 29-14 at the break. Job done, plaudits assured, he was subbed off shortly after 50 minutes, a bigger job in store next weekend. Castres pulled back to within five points, and were driving towards the line once more when one handling error too many stopped them short, with the score at 34-29. The win was welcome – important, even, given the play-off stakes – but manager Yannick Bru will be happier his charges have no serious injury concerns. Challenge Cup finalists Lyon suffered a setback six days before they meet Bath for the title, giving up an early 17-0 lead to lose 31-30 at Stade Francais. The result, Stade's first win since March 22, moved them out of the bottom two. Perpignan slipped into the relegation play-off spot after their 31-13 loss at Clermont. Meanwhile, bottom side Vannes led 25-12 after half-an-hour at fourth-placed Bayonne. But the hosts roared back in the second period to win 38-32 and guarantee their place in the post-season race for the Brennus. Toulon fell to a third Top 14 defeat in a row, coming out on the wrong end of a 25-21 scoreline at Pau, as their top-two challenge falters. Leaders Toulouse, too, slipped to a surprise loss at home, beaten 37-35 by a determined Racing 92, who are back on the fringes of the play-off hunt, something that seemed an impossibility after Stuart Lancaster was removed from his post earlier this year.
